Author/Editor		Poljak, Mario
Title		Cepiva proti rotavirusnim okužbam
Translated title		Rotavirus vacciens
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 46, št. Suppl 2
Publication year		2007
Volume		str. 163-74
Language		slo
Abstract		The clinical research and development of rotavirus vaccines began in the late 1970s, approximately 5 years after the discovery of rotavirusues. Since then the approach has mainly focused on the development of orally administered, live-attenuated vaccines because local intestinal immunity plays a major role in reducing the incidence and severity of disease. Initial vaccine attempts were based on the use of live, attenuated, antigenically related viruses from a non-human host (the so-called Jennerian approach). Athough one of such first-generation vaccines, the bovine RIT4237 vaccine induced high heterotypic protection against severe rotavirus diarrhea in Finnish trials, its development was halted during early 1980x. In 1998, a tetravalent rhesus-human reassortant vaccine RotaShield° (Wyeth-Lederle) was licensed in US for the immunisation of infants, with 3 oral doses administered at 2, 4 and 6 months of age. Almost 1.5 million children were vaccinated with this second-generation vaccine before a temporal association between vaccine administration and gut intussusception was detected. For this reason, RotaShield° was withdrawn from the market in October 1999 and this removal created a pressing need for the development of new, safer rotavirus vaccines. (Abstract truncated at 2000 characters)
Descriptors		ROTAVIRUS INFECTIONS ROTAVIRUS VIRAL VACCINES